Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Apr 27, 2014; 6(4): 199-206
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.199
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.199
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease
Zeynel Abidin Ozturk, Department of Internal Medicine, Faculty of Medicine, University of Gaziantep, 27000 Gaziantep, Turkey
Abdurrahman Kadayifci, Division of Gastroenterology, Faculty of Medicine, University of Gaziantep, 27000 Gaziantep, Turkey
Abdurrahman Kadayifci, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, United States
Author contributions: Ozturk ZA and Kadayifci A both contributed to this paper.
Correspondence to: Dr. Abdurrahman Kadayifci, MD, 3-H GI Associates, Zero Emerson Place, Blossom St. Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, United States. akadayifci@mgh.harvard.edu
Telephone: +1-857-9199934 Fax: +1-617-7245997
Received: October 28, 2013
Revised: February 27, 2014
Accepted: March 11, 2014
Published online: April 27, 2014
Revised: February 27, 2014
Accepted: March 11, 2014
Published online: April 27, 2014
Core Tip
Core tip: Non-alcoholic fatty liver disease (NAFLD) is increasing significantly due to the obesity epidemic. Insulin resistance, mainly caused by obesity, plays a primary role in NAFLD pathogenesis. Medications that improve insulin sensitivity are theorized to be useful in the treatment of NAFLD. Therefore, recent studies have explored the role of insulin sensitizers to improve biochemical and histological features of NAFLD.